Us Congress 2025-2026 Regular Session All Bills (Page 255)
Page 255 of 597
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4429
Introduced
7/16/25
Refer
7/16/25
To require the Securities and Exchange Commission to revise the definition of a qualifying investment, for purposes of the exemption from registration for venture capital fund advisers under the Investment Advisers Act of 1940, to include an equity security issued by a qualifying portfolio company and to include an investment in another venture capital fund, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB443
Introduced
1/15/25
Refer
1/15/25
<p><strong>Parris Island Protection Act</strong></p><p>This bill prohibits the use of federal funds to close or realign Marine Corps Recruit Depot, Parris Island in South Carolina, or to conduct any planning or other activity related to such closure or realignment.</p>
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4430
Introduced
7/16/25
Refer
7/16/25
Report Pass
7/22/25
To lower the aggregate market value of voting and non-voting common equity necessary for an issuer to qualify as a well-known seasoned issuer.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4431
Introduced
7/16/25
Refer
7/16/25
To amend the Investment Company Act of 1940 with respect to the definition of qualifying venture capital funds, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4432
Introduced
7/16/25
Refer
7/16/25
To amend the Water Resources Development Act of 1992 with respect to the authorized use of certain user fees collected for recreation sites, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4433
Introduced
7/16/25
Refer
7/16/25
To amend the Federal Food, Drug, and Cosmetic Act to ban certain substances in cosmetic products, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4434
Introduced
7/16/25
Refer
7/16/25
To amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the supply chain transparency needed for companies to make safe cosmetics, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4435
Introduced
7/16/25
Refer
7/16/25
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency with respect to cosmetic ingredients, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4436
Introduced
7/16/25
Refer
7/16/25
To amend the Public Health Service Act with respect to cosmetic safety, with an emphasis on communities of color and professional salon workers, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4437
Introduced
7/16/25
Refer
7/16/25
Report Pass
7/22/25
To reduce the regulatory burden on certain well managed and well capitalized financial institutions, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4438
Introduced
7/16/25
Refer
7/16/25
To prohibit the Board of Governors of the Federal Reserve and the Secretary of the Treasury from issuing a central bank digital currency, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4439
Introduced
7/16/25
Refer
7/16/25
To modernize unemployment compensation benefits.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB444
Introduced
1/15/25
Refer
1/15/25
To amend the Internal Revenue Code of 1986 to permit individuals eligible for Indian Health Service assistance to qualify for health savings accounts.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4440
Introduced
7/16/25
Refer
7/16/25
To amend title 5, United States Code, to require agencies to provide official personnel record files to Federal employees and former Federal employees, and for other purposes.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB4441
Introduced
7/16/25
Refer
7/16/25
To amend title XVIII of the Social Security Act to improve Medicare beneficiary access to new medical technologies that improve health care quality and outcomes by ensuring that breakthrough devices are eligible for conditional approval under the Medicare New Technology Add-On Payment (NTAP) Program, enabling these medical breakthroughs to be provided to Medicare beneficiaries without unnecessary delay.